Jennifer Lachey - 05 Jan 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
05 Jan 2022
Net transactions value
-$158,205
Form type
4
Filing time
07 Jan 2022, 15:35:43 UTC
Previous filing
15 Dec 2021
Next filing
13 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $795 +2,650 +3.1% $0.3000* 88,350 05 Jan 2022 Direct
transaction KROS Common Stock Sale $159,000 -2,650 -3% $60.00 85,700 05 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -2,650 -2.8% $0.000000 92,605 05 Jan 2022 Common Stock 2,650 $0.3000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.